Squarepoint’s Novo Nordisk NVO Stock Holding History

Squarepoint’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$23.3M	Sell	632,700 -1,448,100	-70%	-$68.6M	0.03%	623
2025 Q4	$106M	Buy	2,080,800 +549,700	+36%	+$28.1M	0.11%	186
2025 Q3	$85M	Buy	1,531,100 +1,049,000	+218%	+$61.4M	0.09%	259
2025 Q2	$33.3M	Sell	482,100 -77,800	-14%	-$5.29M	0.03%	533
2025 Q1	$38.9M	Buy	559,900 +381,900	+215%	+$31.5M	0.05%	424
2024 Q4	$15.3M	Buy	178,000 +80,300	+82%	+$8.68M	0.02%	898
2024 Q3	$11.6M	Buy	97,700 +80,400	+465%	+$10.7M	0.02%	883
2024 Q2	$2.47M	Buy	17,300 +1,000	+6%	+$133K	﹤0.01%	1885
2024 Q1	$2.09M	Buy	+16,300	New	+$1.94M	﹤0.01%	2044

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Squarepoint's NVO Position: Q1 2026 in Review

Squarepoint reduced its Novo Nordisk (NVO) stake by 86% in Q1 2026, selling an estimated $38M and leaving 131,865 shares worth $4.85M. The position accounts for 0.01% of the portfolio, ranked #1530.

Squarepoint first reported a position in NVO in Q2 2019 and has held it in 26 quarters since. The position peaked at $60.4M in Q3 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Squarepoint held 131,865 shares of Novo Nordisk worth $4.85M as of Q1 2026.
Squarepoint sold 802,779 Novo Nordisk shares in Q1 2026, an estimated $38M.
Novo Nordisk made up 0.01% of Squarepoint's portfolio in Q1 2026, its #1530 holding.
Squarepoint first reported a position in Novo Nordisk in Q2 2019 and has held it in 26 quarters since.
Squarepoint's Novo Nordisk position peaked at $60.4M in Q3 2025.
1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.